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Purpose. To determine the human jejunal permeability of cimetidine
and ranitidine using a regional jejunal perfusion approach, and to
integrate such determinations with previous efforts to establish a
baseline correlation between permeability and fraction dose ab-
sorbed in humans for soluble drugs.
Methods. A sterile multi-channel perfusion tube, Loc-I-Gut®, was
inserted orally and positioned in the proximal region of the jejunum.
A solution containing cimetidine or ranitidine and phenylalanine,
propranolol, PEG 400, and PEG 4000 was perfused through a 10 cm
jejunal segment in 6 and 8 subjects, respectively.
Results. The mean Peff (± se) of cimetidine and ranitidine averaged
over both phases were 0.30 (0.045) and 0.27 (0.062) × 10−4 cm/s,
respectively, and the differences between the two were found to be
statistically insignificant. The mean permeabilities for propranolol,
phenylalanine, and PEG 400 averaged over both phases and studies
were 3.88 (0.72), 3.36 (0.50), and 0.56 (0.08) × 10−4 cm/s, respectively.
The differences in permeability for a given marker were not signifi-
cant between phases or between the two studies.
Conclusions. The 10-fold lower permeabilities found for cimetidine
and ranitidine in this study, compared to propranolol and phenylal-
anine, appear to be consistent with their less than complete absorp-
tion in humans.
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INTRODUCTION
The oral bioavailability of a drug is affected by several
factors such as dissolution, transit time, intestinal permeabil-
ity and first pass metabolism in the gut and/or liver. Of these,
the intestinal permeability is a major determinant of extent of
drug absorption and quantitatively represents the fundamen-
tal membrane transport coefficient of the intestinal mucosa of
the drug (1). The primary objective of the present study was
to evaluate the relationship between effective human jejunal
permeability, Peff, and the pharmacokinetic parameters of
rate and extent of absorption of the H2 receptor antagonists,
cimetidine, and ranitidine, using the regional jejunal perfu-
sion methodology (2–4). An important secondary objective of
these studies was to integrate such determinations of in vivo
permeabilities with previous efforts to establish a baseline
correlation between permeability and fraction dose absorbed
in humans for soluble drugs. Such efforts may also allow the
establishment of simple correlations between human jejunal
permeabilities and permeabilities from animal and tissue cul-
ture and facilitate pre-clinical estimation of human absorp-
tion. Such simple, rapid, and inexpensive screening proce-
dures would eventually aid in determining the biopharmaceu-
tic classification of drugs for both the setting and




Cimetidine and ranitidine were obtained from Smith-
Kline Beecham Pharmaceuticals (Philadelphia, PA) and
Glaxo Wellcome Pharmaceuticals (Research Triangle Park,
NC), respectively. Propranolol and phenylalanine were pur-
chased from Ayerst Laboratories, Inc. (Philadelphia, PA) and
Twin Laboratories, Inc. (Ronkonkoma, NY), respectively.
Polyethylene glycol (PEG) 400, 1000, 1500, and 4000 were
obtained from Union Carbide Chemicals and Plastic Com-
pany, Inc. (Danbury, CT). Mannitol, NaH2PO4 ? H2O,
Na2HPO4, glucose, KCl, and NaCl of USP or NF grade were
used to prepare the perfusate, and were purchased from Spec-
trum Chemical Mfg. Corp. (Gardena, CA) and Abbott Labo-
ratories (North Chicago, IL). All solvents used in the assays
were of HPLC grade.
The perfusates contained 1 mM cimetidine or 0.5 mM
ranitidine, 0.003 mM propranolol, 0.06 mM phenylalanine,
12.5 mM PEG 400, 1.5 mM PEG 4000, 35 mM mannitol, 5
mM KCl, 49 mM NaH2PO4 ? H2O, 21 mM Na2HPO4, 10 mM
glucose, and 45 mM NaCl. The final osmolality and pH of the
perfusate solutions were adjusted to 290 mOsm/l and 6.5, re-
spectively.
Subjects
All subjects gave written informed consent to participate
in the study that followed the tenets of the Declaration of
Helsinki promulgated in 1964, and was approved by the In-
stitutional Review Board at the University of Michigan Medi-
cal Center. All subjects were between the ages of 18–40 years,
and were judged healthy based on medical history, physical
examination, and laboratory tests prior to the study period.
Experimental Procedures
Following an overnight fast, the intubation of the perfu-
sion tube and perfusion of the jejunal segment with the drug-
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containing solution, at a rate of 3 ml/min or 2 ml/min for two
90-min periods, was performed according to the protocol de-
scribed earlier (4).
Drug Analysis
The concentrations of cimetidine, PEG 4000, PEG 400,
propranolol, and phenylalanine were determined by high per-
formance liquid chromatography (HPLC) methods. The
HPLC system was described earlier (4). For cimetidine, the
mobile phase was composed of 0.067 M potassium-sodium
phosphate buffer containing potassium chloride 10 g/liter and
acetonitrile (60:40 %, v/v) (5). The separation was performed
on a Nucleosil 100SA ion exchange column (10 mm, 250 × 4.6
mm, Alltech). The UV absorption was recorded at 228 nm
and ranitidine was used as an internal standard. The mixture
of the perfusate sample (0.1 ml) and the internal standard
solution (250 ml, 200 mg/ml) was filtered (0.45 mm, Acro-
disc®, Gelman Sciences), and 20 ml was injected onto the
column. The retention times of cimetidine and ranitidine
were 7.3 and 14.3 min, respectively. The intraday coefficient
of variation (CV) was 1.53 and 0.89 %, and the interday CV
was 15.91 and 6.52 %, at 40 mg/ml and 320 mg/ml, respec-
tively. The detection limit was 8 mg/ml. Ranitidine was as-
sayed using the method of Prueksaritanont et al. (6). Analyses
of PEG 4000, PEG 400, propranolol, and phenylalanine were
carried out using previously described methods (4).
Data Analysis
Estimation of Effective Permeability Coefficients
The estimation of effective permeability, Peff, was carried
out using the methodology described previously (4,7–10). The
effective permeability coefficients obtained after excluding
outliers were then normalized to a fixed segmental radius of
1.75 cm. The mean of the normalized effective permeabilities
was then used to calculate the fraction of drug absorbed.
Fraction Dose Absorbed
The fraction dose absorbed, Fa, was estimated using
methodology described previously (8).
RESULTS AND DISCUSSION
The estimates of the effective permeabilities, Peff, at
steady state for cimetidine and the reference compounds ob-
tained from both perfusion phases at the 2 flow rates, 2 ml/
min and 3 ml/min, were found to be statistically insignificant
(p > 0.1). Thus, the mean effective permeabilities of cimeti-
dine and the reference compounds at the 2 flow rates for both
perfusion periods, along with those obtained for ranitidine
and the reference compounds for the 2 perfusion periods at 2
ml/min, are shown together in Table I. Both cimetidine and
ranitidine exhibited low jejunal permeability relative to the
reference compounds propranolol and phenylalanine, consis-
tent with the incomplete absorption observed for both of
these drugs (11). The fraction dose absorbed, estimated as-
suming a mean small intestinal residence time of 3 h and an
intestinal radius of 1.75 cm, was about 30% for both cimeti-
dine and ranitidine. This value is at the low end of the highly
variable absorption reported for cimetidine (40–90%) and in
reasonable proximity to that of 50% observed for ranitidine.
The possibility of a significant decrease in the permeability of
cimetidine at concentrations greater than 0.4 mM, similar to
that reported in both rat jejunum and ileum cannot be ruled
out (12). It is also possible that the perfusate pH of 6.5 may
have lowered permeability to some extent. More accurate
estimates would require consideration of transit, position de-
pendent permeability, motility, and lumenal composition
(e.g., pH) variation, as well as the impact of metabolism and
P-glycoprotein efflux mechanisms, and is beyond the scope of
this report (12,13). The estimated absorption for propranolol
and phenylalanine was 100%.
The overall mean permeabilities for the various com-
pounds, along with the overall mean values from a previous
study with piroxicam normalized to a segmental radius of 1.75
cm, are shown in Table II and Fig. 1. The mean permeabilities
Table I. Effective Permeabilities of Cimetidine and Ranitidine and













1 Cimetidine 0.296 0.139 0.47 7 0.053
2 Cimetidine 0.304 0.198 0.65 5 0.089
1 Propranolol 4.141 2.185 0.53 8 0.773
2 Propranolol 2.747 1.309 0.48 6 0.534
1 Phenylalanine 4.023 2.081 0.52 8 0.736
2 Phenylalanine 3.653 2.282 0.62 6 0.932
1 PEG 400 1.043 0.419 0.40 8 0.148
2 PEG 400 0.818 0.193 0.24 6 0.079
1 Ranitidine 0.338 0.283 0.84 8 0.100
2 Ranitidine 0.208 0.203 0.98 8 0.072
1 Propranolol 4.744 6.240 1.32 8 2.206
2 Propranolol 3.596 4.152 1.15 8 1.468
1 Phenylalanine 3.339 3.994 1.20 8 1.412
2 Phenylalanine 2.511 2.402 0.96 8 0.849
1 PEG 400 0.248 0.131 0.53 8 0.046
2 PEG 400 0.193 0.128 0.66 8 0.045






Propranolol Phenylalanine PEG 400 Piroxicam
This study Ref 4 This study Ref 4 This study Ref 4 Ref 4
Mean Peff, ×104 0.299 0.273 3.878 2.698 3.363 4.313 0.559 0.555 6.738
sd Peff, ×104 0.157 0.247 3.940 1.192 2.743 2.112 0.446 0.381 3.933
n 12 16 30 10 30 11 30 11 11
CV 0.53 0.91 1.02 0.44 0.82 0.49 0.80 0.69 0.58
se Peff, ×104 0.045 0.062 0.719 0.377 0.501 0.637 0.082 0.115 1.186
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of piroxicam and the reference compounds reported in a pre-
vious study (4) were determined using a segmental intestinal
radius in each subject that was calculated from segmental
volume estimates and then normalized to a fixed radius of
1.15 cm. The mean effective permeabilities (± sd) for piroxi-
cam, phenylalanine, propranolol, and PEG 400, obtained in
the previous study (4) estimated using an intestinal segment
radius of 1.15 cm, was 10.40 ± 5.93, 6.67 ± 3.42, 3.59 ± 1.60,
and 0.80 ± 0.46 × 10−4 cm/sec, respectively. The mean effec-
tive permeabilities (± sd) for phenylalanine, propranolol, and
PEG 400, in the present study normalized to an intestinal
radius of 1.75 cm, was 3.36 ± 2.74, 3.88 ± 3.94, and 0.56 ± 0.45
× 10−4 cm/s, respectively. The value of 1.75 cm was adopted
for normalization of permeabilities based on x-ray analysis of
barium perfusion studies (2, Lennernas, Personal Communi-
cation). The two sets of values can be inter-converted using
the ratios of the radii. Thus, the mean effective permeabilities,
from the previous study, can be recalculated by multiplication
with the factor, 1.15/1.75 or 0.657, to give mean effective per-
meabilities (± sd) of 6.74 ± 3.93, 4.31 ± 2.11, 2.70 ± 1.19, and
0.56 ± 0.38 × 10−4 cm/sec, for piroxicam, phenylalanine, pro-
pranolol, and PEG 400, respectively. The two sets of values
normalized to a fixed radius of 1.75 cm (Table II and Fig. 1)
indicate clearly that a normalized standard procedure is es-
sential for comparison of data obtained from various sets of
permeability determinations.
In conclusion, the results of the present study further
support the utility of the perfusion methodology for deter-
mining human jejunal permeabilities and their correlation
with human oral absorption. These determinations constitute
an important addition to the database that can be utilized in
the construction of several useful correlations. Thus, correla-
tions of human permeability estimates with fraction dose ab-
sorbed and with permeabilities from other animal or tissue
culture systems would allow both the permeability-
classification of drugs (14) as well as the setting of bioequiva-
lence standards for drug product approval.
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Fig. 1. Comparison of effective permeabilities of various compounds.
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